IDO1 and melanoma: The 2018 phase 3 clinical trial (NCT02752074) that examined the effectiveness of combining an IDO1 inhibitor, epacadostat, with the checkpoint inhibitor pembrolizumab found that melanoma patient progression-free survival was not improved.